Key statistics
On Friday, Actinium Pharmaceuticals Inc (7AY1:BER) closed at 1.66, 8.20% above its 52-week low of 1.54, set on Sep 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.68 |
---|---|
High | 1.69 |
Low | 1.64 |
Bid | 1.53 |
Offer | 1.72 |
Previous close | 1.69 |
Average volume | 2.79k |
---|---|
Shares outstanding | 31.15m |
Free float | 30.52m |
P/E (TTM) | -- |
Market cap | 56.08m USD |
EPS (TTM) | -1.52 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 19:21 BST.
More ▼
Press releases
- Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
- Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.
- Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications
- Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
- Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
More ▼